Long noncoding RNA MAFG‑AS1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells through downregulation of miR‑6852

• Published in: Experimental and therapeutic medicine Vol. 18; no. 4; pp. 2547 - 2553
• Main Authors: Ouyang, Hui, Zhang, Li, Xie, Zhen, Ma, Simin
• Format: Journal Article
• Language: English
• Published: Athens Spandidos Publications 01.10.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Antisense RNA; Binding sites; Bone cancer; Cancer; Cancer genetics; Cancer research; Cancer therapies; Carcinoma; Cell cycle; Colorectal cancer; Genetic aspects; Genomes; Genomics; Hepatocellular carcinoma; Kinases; Liver cancer; Lung cancer; Metastasis; MicroRNA; Pathogenesis; Polymerase chain reaction; RNA; Scientific equipment industry; Transcription (Genetics); Transcription factors; Tumors; United States; China
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2019.7850

Long noncoding RNAs (lncRNAs) have been shown to participate in the development and progression of a number of different types of cancer, including hepatocellular carcinoma (HCC). A recent report has indicated that lncRNA MAFG-antisense 1 (AS1) promotes colorectal cancer. However, the role of MAFG-AS1 in other types of cancer remains unclear. The aim of the present study was to examine the effect of lncRNA MAFG-AS1 in HCC. Based on The Cancer Genome Atlas database and reverse transcription-quantitative PCR results, it was determined that lncRNA MAFG-AS1 expression was increased in HCC tissues and cell lines. Following knockdown of lncRNA MAFG-AS1, a Cell Counting Kit-8 assay and Transwell assay demonstrated that the proliferation, migration and invasion of HCC cell lines were significantly inhibited. It was additionally demonstrated that there was a negative regulatory association between lncRNA MAFG-AS1 and miR-6852. Inhibition of miR-6852 increased proliferation, migration and invasion of HCC cell lines. LncRNA MAFG-AS1 promoted HCC development by dampening miR-6852 function and may thus be a novel target for treating patients with HCC.